C86.4 Blastic NK-cell lymphoma

Name of the Condition

• Blastic NK-cell lymphoma
• ICD-10 Code: C86.4

Summary

Blastic NK-cell lymphoma is a rare, aggressive type of non-Hodgkin lymphoma originating from natural killer (NK) cells. It is characterized by the proliferation of immature NK cells and typically presents with systemic symptoms. The disease may involve bone marrow, lymph nodes, or other tissues and can progress rapidly if untreated.

Causes

The exact cause involves genetic mutations in NK cells leading to uncontrolled proliferation. Epstein-Barr virus (EBV) infection is frequently associated with this condition, particularly in immunocompromised individuals. Immune system dysregulation and environmental factors may also contribute to its development.

Risk Factors

• Epstein-Barr virus (EBV) infection
• Immunosuppression (e.g., from medications or HIV)
• Male gender
• Advanced age
• Prior exposure to certain chemicals or radiation
• Ethnic background (more common in certain populations)

Symptoms

• Fever, night sweats, or unexplained weight loss
• Fatigue or weakness
• Enlarged lymph nodes (lymphadenopathy)
• Bone marrow involvement (leading to cytopenias)
• Skin lesions or rashes
• Abdominal pain or swelling (if organ involvement)

Diagnosis

Diagnosis involves a physical examination, followed by biopsy of affected tissue to confirm lymphoma type. Imaging (CT, PET) assesses disease extent, and blood tests evaluate cell counts and organ function. Flow cytometry and immunohistochemistry identify NK-cell markers, while molecular testing detects EBV association.

Treatment Options

Treatment typically includes multi-agent chemotherapy regimens, such as CHOP or more intensive protocols. Stem cell transplantation may be considered for eligible patients. Supportive care addresses cytopenias or organ dysfunction. Clinical trials may offer alternative options for refractory cases.

Prognosis and Follow-Up

Prognosis is generally poor due to the aggressive nature of the disease. Regular follow-up with imaging and blood tests monitors for recurrence. Long-term survival depends on response to treatment and disease stage at diagnosis.

Complications

• Rapid disease progression
• Bone marrow failure (cytopenias)
• Organ dysfunction (e.g., liver, spleen)
• Infections due to immunosuppression
• Treatment-related toxicities

Lifestyle & Prevention

• Maintain a healthy immune system through balanced nutrition and regular exercise.
• Avoid known environmental risk factors (e.g., excessive radiation exposure).
• Manage underlying conditions (e.g., HIV) to reduce immunosuppression.
• Seek prompt medical attention for persistent symptoms.

When to Seek Professional Help

Consult a healthcare provider if experiencing unexplained fever, weight loss, fatigue, or enlarged lymph nodes. Immediate care is needed for signs of severe cytopenias (e.g., bleeding, infection) or organ dysfunction.

Tips for Medical Coders

Document the presence of EBV association, disease stage, and treatment response when available. Ensure biopsy results and imaging reports support the diagnosis. Code C86.4 is specific to blastic NK-cell lymphoma; verify no other specified lymphoma type applies.